NCT00773747 2021-04-30Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)Merck Sharp & Dohme LLCPhase 3 Completed637 enrolled 15 charts
NCT01266057 2021-03-04Sirolimus or Vorinostat and Hydroxychloroquine in Advanced CancerM.D. Anderson Cancer CenterPhase 1 Completed143 enrolled
NCT01132911 2017-07-02A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including CNS Tumors and LymphomasNational Institutes of Health Clinical Center (CC)Phase 1 Completed5 enrolled
NCT00750178 2017-04-07A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0683 in Patients With Advanced Cancer (0683-008)Merck Sharp & Dohme LLCPhase 1 Completed30 enrolled
NCT00373490 2015-08-27A Study of Oral Suberoylanilide Hydroxamic Acid (Vorinostat) in Patients With Solid Tumors (0683-048)Merck Sharp & Dohme LLCPhase 1 Completed16 enrolled 13 charts
NCT00045006 2013-05-30Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced CancerNational Cancer Institute (NCI)Phase 1 Completed